Intrathecal ziconotide: A review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics

CNS Drugs

Volumn 27, Issue 11, 2013, Pages 989-1002

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; PLACEBO;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AIDS RELATED PAIN; AMBLYOPIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BRAIN DISEASE; CANCER PAIN; CHILL; CHRONIC PAIN; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOLLOW UP; GAIT DISORDER; HALLUCINATION; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; MALIGNANT HYPERTHERMIA; MALIGNANT NEOPLASTIC DISEASE; MANIA; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENINGITIS; MONOTHERAPY; MYASTHENIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; NAUSEA AND VOMITING; NEURALGIA; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NONCANCER RELATED PAIN; NONHUMAN; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STUPOR; SUICIDE; THORAX PAIN; TREATMENT RESPONSE; URINE RETENTION; VERBAL BEHAVIOR; VESTIBULAR DISORDER; VISUAL DISORDER;

ANALGESICS, NON-NARCOTIC; CHRONIC PAIN; DRUG RESISTANCE; HUMANS; INJECTIONS, SPINAL; OMEGA-CONOTOXINS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84887041121     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0107-5     Document Type: Review

References (33)

1. Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883-91.
2. Gureje O, Von Korff M, Simon GE, et al. Persistent pain and wellbeing. JAMA. 1998;280(2):147-51.
3. van den Beuken-van Everdingen MHJ, de Rilke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437-49.
4. Hayek SM, Deer TR, Pope JE, et al. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011;14(3):219-48.
5. Deer TR, Smith HS, Burton AW, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283-312.
6. Azur Pharma, Inc. Prialt (ziconotide) injection, solution. US prescribing information; 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021060s006lbl.pdf (Accessed 9 Aug 2013).
7. Schmidtko A, Lotsch J, Freynhagen R, et al. Ziconotide for treatment of severe chronic pain. Lancet. 2010;375(9725):1569-77.
8. Lyseng-Williamson KA, Perry C. Ziconotide. CNS Drugs. 2006;20(4):331-8 (discussion 9-41).
9. Gohil K, Bell JR, Ramachandran J, et al. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res. 1994;653(1-2):258-66.
10. McGuire D, Bowersox S, Fellmann JD, et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol. 1997;30(3):400-3.
11. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43(6):624-36.
12. Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75-86.
13. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31(5):393-406.
14. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63-70.
15. Ellis DJ, Dissanayake S, McGuire D, et al. Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation. 2008;11(1):40-9.
16. Wallace MS, Rauck R, Fisher R, et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg. 2008;106(2):628-37.
17. Webster LR, Fisher R, Charapata S, et al. Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage. 2009;37(3):363-72.
18. Ver Donck A, Collins R, Rauck RL, et al. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation. 2008;11(2):103-11.
19. Munson ML, Saharan V, George S. Analysis of adverse events related to ziconotide intrathecal administration: utilization of the FDA AERS database (abstract). Pharmacoepidemiol Drug Saf (PDS). 2009;18(S1):S84.
20. Maier C, Gockel HH, Gruhn K, et al. Increased risk of suicide under intrathecal ziconotide treatment? A warning. Pain. 2011;152(1):235-7.
21. Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13(3):E175-213.
22. Deer TR, Prager J, Levy R, et al. Polyanalgesic consensus conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436-64 (discussion 64-6).
23. 2 [abstract no. 270]. Pain Pract. 2009;9:91.
24. Burton AW, Deer TR, Wallace MS, et al. Considerations and methodology for trialing ziconotide. Pain Physician. 2010;13(1):23-33.
25. Wallace MS, Kosek PS, Staats P, et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9(3):271-81.
26. Webster LR, Fakata KL, Charapata S, et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008;9(3):282-90.
27. Alicino I, Giglio M, Manca F, et al. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain. 2012;153(1):245-9.
28. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain. 2010;26(7):635-44.
29. Dupoiron D, Bore F, Lefebvre-Kuntz D, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012;15(5):395-403.
30. Raffaeli W, Sarti D, Demartini L, et al. Italian registry on long-term intrathecal ziconotide treatment [Erratum appears in Pain Physician. 2011 Mar-Apr;14(2):217]. Pain Physician. 2011;14(1):15-24.
31. Jazz Pharmaceuticals. Patient registry of intrathecal ziconotide management (PRIZM); 2013. http://clinicaltrials.gov/show/NCT01888120 (Accessed 15 July 2013).
32. Dewilde S, Verdian L, Maclaine GDH. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin. 2009;25(8):2007-19.
33. Jazz Pharmaceuticals. Prialt (ziconotide intrathecal infusion) Navigator Reimbursement and Access Program; 2013. http://www.navigatorprogram.com (Accessed 15 July 2013).